Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson’s disease.
Subject: Parkinson's Disease - PUBLISHED VIA Neurobiology of Disease
Author(s):
Lastres-Becker I, Molina-Holgado F, Ramos JA, Mechoulam R, Fernández-Ruiz J
View Source >>
(Price: $40)
Related Studies:
Prospects for cannabinoid therapies in basal ganglia disorders.
Published via British Journal of Pharmacology
Effects of cannabidiol in the treatment of patients with Parkinson’s disease: an exploratory double-blind trial.
Published via Journal of Psychopharmacology
Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson’s disease: importance of antioxidant and cannabinoid receptor-independent properties.
Published via Brain Research
Cannabidiol for the treatment of psychosis in Parkinson’s disease.
Published via Journal of Psychopharmacology
Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson’s disease patients: a case series.
Published via Journal of Clinical Pharmacy and Therapeutics